Telkom has announced that its CEO and executive director Sipho Maseko will step down on 30 June 2022. The telecoms company said the process to appoint a successor is well underway and a designated group CEO will be announced in the not too distant future.
It is possible that cooking oil prevented more looting in South Africa in the last week than the president, the ANC, the intelligence community, the army and the police combined. This, without question, says something about the versatility of the product. It says even more about the state of the state. When you are shown up by canola, you might want to revisit your strategy.ByHoward Feldman
Performance Media across Search, Social and Programmatic platforms is the single fastest growing area of digital media in South Africa. Combine that with the detailed analysis of campaign management, tagging and ad operations, and it becomes apparent that these highly specialist functions require a highly specialised unit.
The Transnet Port Terminals website has been hacked, implying that all companies under Transnet have been affected. All Transnet websites were down at the time when reporting was done for this SA Trucker article. The publication cited sources who requested to remain anonymous because they are not allowed to speak to the media.
The Covid-19 pandemic has hit South Africa's small business sector hard and there are grim statistics to bear this out. Those statistics will not be repeated here. After all, if you are a small business owner setting out on the road to recovery, the last thing you probably want is more details of the toll the pandemic has taken on small enterprises. Far more useful would be some good, solid tips on how to build back better after any business setbacks.ByAmeen Hassen
In October 2020, South Africa and India called on World Trade Organisation (WTO) members to support a proposal to suspend the WTO's agreement on Trade-Related Aspects of Intellectual Property Rights (Trips), for the duration of the coronavirus pandemic.
The thinking behind the proposal is that, if patent rights are waived, vaccine production facilities can be established throughout the world, resulting in increased vaccine supply and expedited roll-out.
On US President Biden’s 100th day in office, the US agreed that it, too, would support a temporary and targeted waiver of Covid-19 vaccine intellectual property (IP) protection, with Canada, New Zealand and the European Patent Office swiftly following suit. 
On the other hand, countries still withholding support for the waiver include the UK, Australia, Japan, Switzerland, Norway, and Brazil, at the time of writing.
In its Position Statement of 7 May 2021, the Max Planck Institute for Innovation and Competition presented a number of reasons why, although well-intentioned, such a waiver would not “be a necessary and suitable measure towards the pursued objectives”.
One of the reasons put forward is that such a waiver of IP rights will not waive the regulatory requirements for vaccine authorisation, which are incredibly onerous and require significant resources to comply with.
In this article, we explore what South Africa’s regulatory requirements are when it comes to vaccine authorisation and whether, in view of these requirements, a waiver of IP protection would actually speed up vaccine delivery and the time to global immunity for Covid-19.
South Africa’s pharmaceutical sector is primarily regulated by the Medicines and Related Substances Act 101 of 1965, and its regulations. This legislation is administered by the South African Health Products Regulatory Authority (SAPHRA).
The legislation says that any entity selling a medicine, medical device or IVD (in vitro diagnostic) for human or animal use must obtain authorisation from the SAHPRA. A “medicine” includes any substance or mixture of substances used, or manufactured or advertised for use in diagnosis, treatment, mitigation, modification or prevention of disease, abnormal physical or mental state, or related symptoms.
Currently, the available vaccines for Covid-19 are all biological medicinal products.
Generally, for biological products, any entity wishing to register a biosimilar medicine, i.e. a “generic” version of a biological medicine, must follow the guidelines issued by the SAHRPA. This includes providing evidence of biosimilarity, and thus the registration requirements are simplified.
But, according to the SAHPRA Guideline on biosimilar medicines registration requirements, vaccines, even if manufactured by recombinant DNA technology, are excluded. As a result, vaccines are presumably required to be assessed via the more stringent general product registration process.
In November 2020, the SAHPRA issued a communication aimed at prospective registrants for candidate Covid-19 vaccines. Its guidance must be followed by all applicants for registration of Covid-19 vaccines.
While the SAHPRA has committed to adopting a priority/expedited review approach to applications relating to Covid-19 management, it is also committed to maintaining a high quality and standard of review. This means that applicants for registration will still be required to submit the requisite non-clinical and clinical data to obtain vaccine registration.
The SAHPRA has recently decided to harmonise some of the SAHPRA medicine policies and procedures with those of the European Medicines Agency (EMA), to reflect global best practice in terms of the safety, quality and efficacy of health product regulation. The threshold for the information and data required for registration of a vaccine product is therefore high.
In terms of SAHPRA guidelines, the following information should be submitted in line with the format and organisation prescribed by EMA guidelines:
Information on the quality of a Covid-19 vaccine product
Information on bioavailability
International studies on pharmacodynamics, pharmacokinetics, safety and efficacy across an international patient population
In addition, to apply for the registration of a Covid-19 vaccine in South Africa, the applicant must have an establishment licence to manufacture, package/label, test, import, distribute or wholesale a health product (or must apply for such a licence), and must manufacture the vaccine in line with Good Manufacturing Practice (GMP).
Applicants for registration of a Covid-19 vaccine must also submit a risk management plan to address uncertainties in the data submitted and must consider South African-specific issues, like HIV and tuberculosis.
In practice, the information and data required for registration of a vaccine is only available to the vaccine developers, who have invested significant resources in establishing and collecting such data. Of course, they may provide a local partner with the requisite information, but they are unlikely to be willing to cooperate with local applicants for registration of a vaccine, in the absence of the back-stops provided by patent protection.
What we think
Our position is that, even in the absence of any IP rights, the well-intentioned goal of vaccine equity may not be so easy to achieve in practice. The regulatory requirements inherent in getting vaccines to market remain, and they are necessary for human safety.
So, while it may be argued that IP rights in the context of vaccines serve to protect the interests of the pharmaceutical industry, the same cannot be said for the regulatory requirements for registering a vaccine, which serve, critically, to protect the right of the public to safe medicines.
LEGAL DISCLAIMER: This Message Board accepts no liability of legal consequences that arise from the Message Boards (e.g. defamation, slander, or other such crimes). All posted messages are the sole property of their respective authors. The maintainer does retain the right to remove any message posts for whatever reasons. People that post messages to this forum are not to libel/slander nor in any other way depict a company, entity, individual(s), or service in a false light; should they do so, the legal consequences are theirs alone. Bizcommunity.com will disclose authors' IP addresses to authorities if compelled to do so by a court of law.